Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "UK Blood Typing, Grouping and Infectious Disease NAT Screening Market Shares and Strategies, Volume and Sales Segment Forecasts for over 40 Individual Immunohematology and NAT Assays" report has been added to ResearchAndMarkets.com's offering.
The database provides 2024 supplier shares and strategies, 2024-2029 volume and sales forecasts for over 40 immunohematology and NAT assays, as well as comprehensive lists of companies developing or marketing new technologies and products by test, including:
Blood Typing and Grouping Tests
- ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 + IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du)
Infectious Disease Screening Tests
- AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NAT
The companies analyzed in the report include:
- Abbott
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Diagast
- DiaSorin
- Fujirebio
- Grifols
- Hologic
- Immucor
- LabCorp
- Proteome Sciences
- Quest Diagnostics
- QuidelOrtho
- Roche
- Siemens Healthineers
- Tecan
- Thermo Fisher
For more information about this report visit https://www.researchandmarkets.com/r/uz1ezw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
